Arsenic trioxide (ATO), an FDA‐approved drug widely accepted in treating acute promyelocytic leukemia, is also a potent inhibitor of GLI1 and GLI2 and inhibits cancer growth by blocking GLI transcription.392. This evidence concerns the gene GLI1 and cancer.